Cover Image
Market Research Report

Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

Published by Mordor Intelligence LLP Product code 353906
Published Content info 116 Pages
Delivery time: 2-3 business days
Back to Top
Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
Published: February 1, 2019 Content info: 116 Pages

Market Overview

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives toward cervical cancer prevention, the growing prevalence of cervical cancer, an increase of awareness regarding early diagnosis, and strong R&D from key players for cervical cancer diagnosis and drugs.

The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women, worldwide. According to the World Health Organization (WHO), more than 270,000 women die every year due to cervical cancer. The cervical cancer mortality rate is higher in developing countries, due to improper detection at early stages of the disease. With the rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer, the market is expected to grow.

Increasing awareness among the general population regarding the care, prevention, and treatment of cervical cancer, the rise in certain behaviors such as sex with multiple-partners and smoking, certain genetic factors, and weak immune system are all linked to the growth of the cervical cancer diagnostics and therapeutics market.

Awareness programs have helped in the growth of the market. For instance, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening, every two years. These programs were found to be responsible for the growth of the overall market.

Scope of the Report

Cervical cancer refers to a malignancy of cervical cells. More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The most common types of cervical cell cancer are squamous cell malignancy and adenocarcinoma. Cervical cancer diagnostic tests are being widely used for the detection of precancerous or cancerous lesions in the cervix of females.

Key Market Trends

Pap Smear Test, the Largest Segment Under Diagnostic Test, is Expected to Grow During the Forecast Period

Pap smear test, the most effective tool for the diagnosis of HPV, was found to be the most revenue-generating segment. Factors, such as the increasing prevalence of HPV infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are promoting the growth of the market.

North America, which Holds the Largest Share in the Market, is Expected to Follow the Same Trend, Over the Forecast Period

North America is the largest market for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which has increased the reach of insurance coverage for cervical screening tests, especially for low-income women.

Asia-Pacific, the fastest growing market for cervical cancer diagnostic tests, attributes its growth to the increasing prevalence of cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea, and Australia.

Competitive Landscape

Intense competition was observed in the market for cervical cancer diagnostics and therapeutics, due to the presence of a large number of cervical cancer patients. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 56560

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Favorable Government Initiatives Toward Cervical Cancer Prevention
    • 4.2.2 Growing Prevalence of Cervical Cancer
    • 4.2.3 Increasing Awareness Regarding Early Diagnosis
    • 4.2.4 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
  • 4.3 Market Restraints
    • 4.3.1 Economic Constraints in Many Countries to Adopt Regular Testing Procedures
    • 4.3.2 High Cost of Cancer Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Diagnostic Test
    • 5.1.1 Pap Smear Test
    • 5.1.2 HPV Test
    • 5.1.3 Colposcopy
    • 5.1.4 Biopsy and Endocervical Curettage
    • 5.1.5 Other Diagnostic Tests
  • 5.2 By Therapeutic
    • 5.2.1 Avastin (Bevacizumab)
    • 5.2.2 Blenoxane (Bleomycin)
    • 5.2.3 Hycamtin (Topotecan Hydrochloride)
    • 5.2.4 Gemcitabine-Cisplatin
    • 5.2.5 Vaccines
      • Gardasil
      • Cevarix
    • 5.2.6 Other Therapeutics
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Specilty Clinics
    • 5.3.3 Cancer and Radiation Therapy Centers
    • 5.3.4 Diagnostic Centers
  • 5.4 Geography
    • 5.4.1 North America
      • US
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Bristol-Meyrs Squibb Company
    • 6.1.3 GlaxoSmithKline PLC
    • 6.1.4 Merck & Co. Inc.
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Qiagen NV
    • 6.1.7 Advaxis Inc.
    • 6.1.8 Becton, Dickinson and Company
    • 6.1.9 F. Hoffmann-La Roche Ltd


Back to Top